Skin biopsy specimens, infiltrating cells, and overall survival. Immunohistochemical analysis of representative skin biopsy specimen (A), the cell count distribution of CD8⁺, CD163⁺, and CD1a⁺ cells (B), and the impact of MM on OS (C-D). (A) Tissue sections of skin biopsy were stained with hematoxylin and eosin (ai,bi,ci), or antibodies to CD8⁺ (aii, bii, cii), or CD163⁺ (aiii, biii, ciii) as detailed in “Methods.” Shown are representative specimens of an MT/FM patient (ai-iii), a MT/MM patient (bi-iii), and an FT/MM patient (ci-iii). Original magnifications ×200. (B) Distribution of infiltrating cell counts (Bi, CD8⁺; Bii, CD163; and Biii, CD1a). (C) OS according to CD163⁺ cell counts (≤ 200 [FM] vs > 200 [MM]) in all patients. OS of patients with MM was significantly lower than that of those with FM (FM: 66.2% ± 10.6% at 1 year and 58.3% ± 11.4% at 3 years, MM: 37.8% ± 21.0% at 1 year and 37.8% ± 21.0% at 3 years, respectively; P = .005). (D) OS according to CD163⁺ cell counts (≤ 200 vs > 200) in 46 patients undergoing steroid treatments. OS of patients with MM was significantly lower than that of those with FM (FM: 57.7% ± 17.1% at 1 year and 50.7% ± 17.4% at 3 years; MM: 18.2% ± 22.7% at 1 year and 18.2% ± 22.7% at 3 years, respectively; P = .002).